IDYA Ideaya Biosciences Inc

Cantor reiterated $IDYA at Overweight and said -- Updated DLL3 ADC, IDE849, data from ~100 patients presented by partner, Hengrui, will be the most important update for IDYA. $AMGN $AZN ABBV ZLAB MRK - DSNKY Cantor added—We should get a first look at data from neuroendocrine carcinomas and landmark OS data in small cell lung cancer (SCLC). In uveal melanoma, we are expecting to see ~100 patients from each of darovasertib's (PKCi) Phase 2 trials in HLA-A2+ metastatic and neoadjuvant patients.

$IDYA MGT believes daro has blockbuster potential in HLA-, which has double the TAM of Kimmtrak’s ~$450M run-rate in HLA+ (1/3 of mUM). Plus all the other tons of best on class and first in class assets. 10b, probably more, easily.

$IDYA I love ❤️ how this is getting demolished on an XBI crush kinda day! Gives me conviction I am in the right spot

$IDYA Volume 5k after 30 minutes. Are you serious? Good enough for a slow bleed as usual. Do not fall for it.

Cantor reiterated an Overweight rating on $IDYA and said -- IDEAYA will have meaningful updates for DLL3 ADC IDE849 at ESMO through partner Hengrui and later this year in SCLC/neuroendocrine cancers. $ZLAB $AMGN AZN ABBV MRK DSNKY Cantor added—The company recently aligned with the FDA on a Ph3 2L+ ESSCLC trial and is positioning IDE849 as potentially best-in-class. The key benchmarks are Zai's zoci and Amgen's Imdelltra, particularly in postimdelltra patients. An underappreciated opportunity may be neuroendocrine cancers, where IDE849 could potentially establish a first-in-class position and an expedited path to approval. Together with a clear path forward in ES-SCLC, the ESMO data should increase investor confidence in IDE849, which has already shown a competitive profile, offering some downside protection. IDEAYA will also host an R&D Day on November 16 focused on its emerging MTAP/CDKN2A and KRAS strategy in PDAC, setting the stage for a PRMT5 data update next year.